CUMULATIVE INDEX 1999

Volume 34

March	HIV/AIDS UPDATE, pages 1–260
June	EMERGING NURSING CARE OF VULNERABLE POPULATIONS, pages 261–407
	CONTEMPORARY INFECTION CONTROL FOR NURSES, pages 409–539
September	NEUROSCIENCE NURSING FOR A NEW MILLENNIUM, pages 541–776
December	WOUND CARE MANAGEMENT, pages 777–982

Note: Page numbers of article titles are in **boldface** type.

Abscess, of brain, pathophysiology of, 764
signs and symptoms of, 765, 766
Acquired immunodeficiency syndrome (AIDS). See also *Human immunodeficiency virus infection.*
and the loss experience, 166–168
attitudes of health care givers toward, from 1996–1998, 38–40
in the early 1990s, 13–19
in the mid to late 1980s, 4–6, 8–10
in the mid-1990s, 28–30
deaths from, grief work of survivors of, **163–177**
health care provider-patient relationships in, **1–48**
in literature from 1996 through 1998, 34–43
in literature of the early 1990s, 11–21
in literature of the mid to late 1980s, 2–11
in literature of the mid-1990s, 21–34
home care for, **201–212**
assessment of patient's and caregiver's knowledge of the disease in, 205–207
assessment of patient's and caregiver's understanding of treatment in, 207, 208
challenges of, 202
establishing a therapeutic nurse-patient-caregiver relationship in, 202–204
helping patient and caregiver negotiate the health care system in, 208, 209
helping patient and caregiver negotiate the legal system in, 209, 210
helping patient and caregiver negotiate the social-welfare system in, 209
needs of caregiver and, 202
needs of persons living with AIDS and, 202
patient-caregiver relationship in, 204, 205
in African Americans, 347
in Asians, 372
in Latinos, 371, 372
in lesbian women, 387, 388
in rural areas, 180
in the United States, demographics of, 201–212
in women. See *Women with acquired immunodeficiency syndrome.*
Adhesives, as cause of skin disruption in infants, 909
Adolescent mothers, adverse birth outcomes in, 293
availability of resources for, 290
child abuse by, 292
depression and suicide attempts in, 291, 292

Adolescent mothers (*continued*)
domestic violence among, 292, 293
health status of, 291–293
health-related problems in, **289–299**
nursing implications of, 295–297
maternal protectiveness in, 294
maternal role transition as a positive force in, 293–295
maternal self-reparation in, 295
relative risk of, 291
sexually transmitted disease in, 293
African Americans, cultural roots of, case study of, 351–353
implications of for health care providers, 350, 351
disparities of health in, **345–357**
health status of, 347, 348
applying theoretical framework to study of, 346, 347
future research on, 353, 354
relative risk for, 349, 350
resource availability for, 348, 349
Ageism, negative health consequences of, 335, 336
Aging, normal, 922
American Medical Association, 530
American Nurses' Association, 530
Amyotrophic lateral sclerosis, 738–741
clinical presentation of, 739, 740
diagnosis of, 740
management of, 740, 741
pathophysiology of, 739
patient and family resources for, 742
Angiography, cerebral, 602
magnetic resonance, 603
subtraction, digital, 602, 603
Annulus fibrosa, 559
Anorexia, in human immunodeficiency virus infection, 137, 138
Anterior cord syndrome, 667
Antiepileptic drugs, adverse effects of, 749
for acute seizure emergencies, 752, 753
for chronic therapy, 748, 749
in the elderly, 752
in women, 752
pharmacokinetics of, 751
principles of treatment with, 750, 752
Antiretroviral therapy(ies), adherence to, assessment of, 116, 117
definition and scope of the problem in, 115, 116
factors associated with, 117–119
individual behavior models of, 119, 120
intervening to improve, 121–125
social context of, 120, 121
future advances in, 108, 109
highly active, adherence to, **113–129**
effectiveness of, 113–115
postponing treatment with, 158
Anxiety, and depression in youth, 401, 403, 404
Apligraft, 944
Arachnoid, 560
Arousal mechanisms, assessment of, 574, 575
Asian immigrants, as vulnerable population, **359–380**
Assessment, neurologic, as foundation for nursing practice, **573–592**
basic tips regarding, 573, 574
level of consciousness in, 574–577
Atherosclerosis, in pathogenesis of stroke, 696
Attention deficit disorder, and depression in youth, 401, 403, 404
Autonomic nervous system, 571, 572
Awareness, assessment of, 575

"Bag technique" for nurse's bag, 479
Basement membrane, 782
Battered women, application of relative risk to, in case study of, 307–310
application of resource availability to, in case study of, 305–307
as vulnerable population, **301–312**
case study of, 303–305
Battering, definition of, 301, 302
Behavior change theory, in prevention of human immunodeficiency virus infection, 57, 61–63
Bereavement, 164, 165
models of, 168–170
Bereavement overload, 167, 168
Beta-lactamase-producing gram-negative bacilli, extended-spectrum, 432, 433
Bloodborne pathogens, occupational exposure to, 495–498
Bovine spongiform encephalopathy, 428, 429
Braden Scale, 861–863
Brain, 560–570
ischemic injury to, pathways of, 696–698
lobes of, frontal, 564, 565
occipital, 566, 567
parietal, 565, 566
temporal, 566
surface of, 561, 562
Brain abscess, pathophysiology of, 764
signs and symptoms of, 765, 766
Brain attack. See *Stroke*.
Brain death, criteria for, 631
Brain injury, traumatic, **637–659**
assessment of, 647–653
brain stem reflexes in, 649–653
level of consciousness in, 647

neurologic signs in, 647–653
pupillary assessment in, 647
diagnostic tests for, 653, 654
future trends in management of, 657
multidisciplinary management of, 655
nurse's role in, 655–657
outcomes of, 654, 655
pathophysiology of, 638–647
diffuse and focal injuries in, 641–643
primary injury in, 641–643
secondary injury in, 643–647
Brain stem, 570
Brown-Séquard syndrome, 666, 667
Burn injury, types of, 789, 791

Cancer, in Asian and Latino immigrants, 370, 371
"Caregiver burden," in wives caring for husbands with dementia, **275–287**
background and related literature on, 276–278
clinical implications of study results of, 284, 285
data analysis in, 281
discussion of results of study of, 283–286
measures of, 280, 281
method of research on, 278–281
policy implications and role of nurse in, 285, 286
recruitment of participants in study of, 279, 280
results of study of, 282, 283
sample used in study of, 279
sources of data on, 278, 279
Carotid artery syndromes, in stroke, 699, 700
Centers for Disease Control and Prevention, 527, 528
Central cord syndrome, 665, 666
Central nervous system, anatomic evaluation of, 593–596
electrical activity and conduction evaluation of, 599–601
infections of, **761–771**
assessment of, 766, 767
diagnostic studies for, 767, 768
future trends in, 770
medical therapy for, 768, 769
pathophysiology of, 763, 764
role of nurse in, 769, 770
signs and symptoms of, 764–766
vulnerable populations for and incidence of, 762, 763
neuroimaging techniques for, 594–596
physiologic evaluation of, 596–599
radiologic studies of, 593, 594
Cerebellum, 569, 570
Cerebral cortex, 560, 561
Cerebral hemispheres, 560–567
Cerebrospinal fluid, 560
Cerebrospinal fluid analysis, in evaluation of central nervous system, 597, 598
Cerebrovascular evaluation, 602–604
Cerebrum, 560–567
Chickenpox, occupational exposure to, 506, 507
prevention of for nurses, 515, 516
Child abuse, by adolescent mothers, 292
Children, pain assessment in, 852
pain management in, nonpharmacologic, 855–858
Chinese medicine, traditional, in human immunodeficiency virus infection, 156–158
Clostridium difficile diarrhea and colitis, 428
Code of ethics for nursing, 634, 635
Cognitive functioning, assessment of, 575, 576
Colitis, from *Clostridium difficile*, 428
Combination antiretroviral drugs, 103
Communicable diseases, prevention of for nurses, at work and home, **509–526**
Competence, 629
Conjunctivitis, prevention of for nurses, 519, 520
Consciousness, assessment of, 574–577
Corpus callosum, 562
Cough, in human immunodeficiency virus infection, 134, 135
Cranial nerves, assessment of, 577–586
Creutzfeldt-Jakob disease, new variant of, 428, 429
Cyclosporiasis, 430
Cytomegalovirus, and pregnant nurses, 523
occupational exposure to, 498, 499

Degenerative disorders, neurologic, **725–742**
Delavirdine, 99, 100
Dementia, husbands with, "caregiver burden" in wives caring for, **275–287**
Department of Health and Human Services, 527
Depression, in adolescent mothers, 291, 292
in lesbian women, 389
in youth, **393–407**
anxiety and, 401
assessment of, 399–401
attention deficit disorder and, 401
biologic vulnerability toward, 399
case study of, 393, 394
dysthymic disorder and, 400, 401
ethnic minority status and, 398, 399
family violence and, 397

Depression (*continued*)
identification and treatment of, 403, 404
low self-esteem and, 398
major depressive disorder and, 400, 401
parent education in prevention of, 402
parental depression and, 397
poor body image and, 398
prevention of and intervention in, 396, 401–405
primary prevention of, 402, 403
psychosocial factors in, 397–399
role of gender in, 398
school problems and, 397, 398
scope and significance of, 395
tertiary care for, 404, 405
vulnerability to, 395–399
Depression in women with acquired immunodeficiency syndrome, 187
Dermagraft, 943
Dermatitis, diaper, 916–918
Dermis, anatomy of, 782–784
Descartes, 148
Diabetes mellitus, in Asian and Latino immigrants, 367–369
Diaper dermatitis, 916–918
Diarrhea, from *Clostridium difficile*, 428
from *Cyclospora*, 430
in human immunodeficiency virus infection, 141
Diarrheal diseases, prevention of for nurses, 521, 522
Didanosine, 97, 98
Diencephalon, 568, 569
Disinfectants, as cause of skin disruption in infants, 910
Disinfection, 483
versus sterilization, versus clean, **483–491**
Domestic violence, and adolescent mothers, 292, 293
Dominance, cerebral, 563
Dressing changes, pain management during, 850–852
Dressings, 940, 941
advanced, 940, 941
categories of, 875
conventional, 940
occlusive versus nonocclusive, 942
primary and secondary, 941
Drug resistance, in Asian and Latino immigrants, 369
Drug use, and human immunodeficiency virus infection epidemic, 50, 51
Dry mouth, in human immunodeficiency virus infection, 140
Dryness, excessive, as cause of skin disruption in infants, 910–912
Dura, 560
Dyspnea, in human immunodeficiency virus infection, 134, 135
Dysreflexia, autonomic, 682

Elderly, access to health care by, 336–338
alcoholism in, 339
as vulnerable population, **333–343**
dietary behaviors of, 338
drug misuse by, 339
employment of, 334
environmental resources of, 336–338
health promotion services for, 339, 340
hospitalized, profiling care and benchmarking best practice in care of, **239–250**
discussion of, 248, 249
factor analysis in, 245, 246
instrumentation used in, 242–244
internal consistency reliability in, 246
literature review and background of, 240–242
methods of, 242–246
results of, 246–248
sample characteristics in, 244
sampling procedure in, 244
housing of, 334, 335
income of, 334
Medicare for, 336, 337
morbidity and premature mortality in, 340
nursing care of, emerging, 341, 342
community and societal responsibilities for, 341
knowledge of community resources and, 341, 342
physical activity of, 339
physiologic decline in, 340
powerlessness of, 335, 336
quality of health care for, 337, 338
relative risk and health status of, 338–340
social status of, 335, 336
social support of, 335
socioeconomic resources of, 333–336
women's issues and, 336
Electrical stimulation, in care of chronic wounds, 944
Electroencephalogram, in evaluation of central nervous system, 599, 600
Electromyoneurography, in evaluation of central nervous system, 601
Encephalitis, pathophysiology of, 764
signs and symptoms of, 765
Enterococci, multidrug-resistant, 430, 431
Epidemics, of violence, poverty and drug use, concurrent with human immunodeficiency virus epidemic, 50, 51

social contributions to, 50–54
stigma and marginalization in, 51–54
Epidermis, anatomy of, 778–782
Epilepsy. See also *Seizures*.
advances in medical treatment of, 748–753
and seizures, **743–759**
imitators of, 746
origin of, 746, 748
self-management education in, 754–756
implications of for nursing practice, 754–757
spectrum of, and care across the curriculum, 756, 757
surgery for, 753, 754
vagus nerve stimulation in treatment of, 753, 754
Escherichia coli, O157:H7, enterohemorrhagic, 431, 432
Ethical decision making, framework for, 624–628
strategies for promoting, 628, 629
Ethical issues in neuroscience nursing, 629–631
in the future, 632, 633
Ethical principles, 623, 624
Ethical theories, 622, 623
Ethics, 62, 621
Evidence-based practice, for wound care, **955–963**
method of, 956–960
versus classic biomedical or social science research, 960, 961
Evoked potentials, in evaluation of central nervous system, 600, 601
Exercise, in human immunodeficiency virus infection, 154–156
Extravasation, intravenous, as cause of skin disruption in infants, 912–914
Exudate, type and amount of, in assessment of chronic wounds, 821–824

Fatigue, in human immunodeficiency virus infection, 134
Feline spongiform encephalopathy, 428
Fever, in human immunodeficiency virus infection, 142
Fissures of brain, 561, 562
Flaps for wound healing, 883–885
compromised, 890, 891
free, 885
muscle, 884, 885
nursing care of, 889–892
patient education about, 891, 892
procedures for, 885–888
skin, 883, 884
Friction injury, as cause of skin disruption in infants, 912
Functional assessment, and resource use, 616, 617
factors that impact, 617–619
for transitions in patient acuity and care, **607–620**
performance of, 609, 610
Functional independence measure, 608, 609
in collaborative practice, 610–613

Ganglia, 561
basal, 567, 568
Gay and bisexual men, alcohol and drug use in, and risk of disease, 318, 320, 321
antigay violence and, 316–318
as vulnerable population, **313–331**
health problems of, **313–331**
implications of for nursing practice, 322–326
high-incidence diseases in, 321, 322
internalized homophobia in, 316–318
stigma, discrimination, and mental health issues of, 314–318
coping with, 315, 316
Gerstmann-Straussler-Scheinker disease, 428, 429
Graft(s), skin. See *Skin grafts*.
Gray matter, 561
Grief, disenfranchised, 166, 167
models of, 168–170
Grief work of human immunodeficiency virus-positive persons and their survivors, **163–177**
children's needs and, 172, 173
implications for nursing research and education, 174, 175
implications of for nursing practice, 170–174
thriving, not merely surviving, and, 173
Grieving process, 164, 165
Gunshot wounds, 899–905. See also *Trauma wounds*.
management of, 900
Gyri of brain, 562

Hantavirus, 433, 434
Harm reduction, in prevention of human immunodeficiency virus infection, 56, 57
Health care marketplace, current, 412–419
aging of nursing workforce in, 414–416

Health care marketplace (*continued*)
infection prevention and control in, 419, 420
inpatient versus outpatient care in, 412–414
nurse-to-patient ratios in, 416, 417
organizational restructuring and, 418, 419
in the next millennium, **411–426**
Health care providers, and acquired immunodeficiency syndrome, burnout and stressors among, 17, 18
concerns and suggestions offered by, 32
Hepatitis, screening for, in persons with human immunodeficiency virus infection, 84
Hepatitis A, occupational exposure to, 499
prevention of for nurses, 519
Hepatitis B, in Asian and Latino immigrants, 370
occupational exposure to, 496–498
prevention of for nurses, 510, 514
Hepatitis C virus, 434, 435
occupational exposure to, 496–498
Herpes simplex virus, occupational exposure to, 499, 500
oral infection by, prevention of for nurses, 522
Heterosexism, and the stigma of human immunodeficiency virus infection, 51, 52
Home care, infection control in, **463–482**
isolation precautions in, 474–477
for airborne infections, 475, 476
for contact-spread infections, 476, 477
for droplet-spread infections, 476
Homeless, as vulnerable population, **261–274**
disability in, 267
environmental resources and, 264, 265
ethical and policy factors related to, 268, 269
health status of, 266–268
human capital and, 262, 263
morbidity in, 266, 267
mortality in, 267, 268
relative risk in, 265, 266
resource availability for, 262–264
social connectedness and, 263, 264
social status of, 263
vulnerability of, case study of, 271, 272
nursing implications of, 269–271
Hospital Infections Program of the National Center for Infectious Disease, 528
Human immunodeficiency virus, in the era of managed care, **227–235**
future of, 232, 233
life cycle of, 95, 96
interruption of, 96–108
occupational exposure to, **213–225**, 498
administrative concerns in, 222, 223
analysis and prevention of, 223, 224
assessment of risk factors in, 216–220
background of, 213, 214
definition of, 214, 215
follow-up, counseling, and education after, 222
immediate treatment of, 216
postexposure management following, 216–224
rationale and explanation of postexposure management to health care worker after, 220, 221
recommendations regarding postexposure management after, 221, 222
risk of transmission by, 215
Human immunodeficiency virus infection. See also *Acquired immunodeficiency syndrome.*
alternative treatments for, case study in, 158–160
evaluation of, **147–162**
and acquired immunodeficiency syndrome, palliative care for, **131–145**
antiretroviral and prophylactic treatments in, **95–112**
in adults and adolescents, guidelines for, 106, 107
antiretroviral resistance in, 104–106
case management in, 86–88
advocacy role of nurses in, 89, 90
community resources and, 90
fiscal resources and, 90, 91
history of, 87
informed consent and careful documentation in, 91
nurse case management assessment in, 88, 89
plan of care in, 89
skills needed for, 88–91
chemistry panel in, 84
combination antiretroviral drugs in, 103
complete blood count and differential in, 84
coordination of primary care effort in, case management in, 86–88
drug-to-drug interactions in, 103, 104
health care provider-patient relationships in, **1–48**
hepatitis testing in, 84
highly active antiretroviral therapy for, adherence to, **113–129**
immunopathogenesis of, 95, 96
in African Americans, 347
in Asians, 372
in Latinos, 371, 372

in lesbian women, 387, 388
initial primary care encounter in, 72–80
cardiovascular and chest examination in, 79
childhood illness review in, 74
dermatologic assessment in, 78
determining the clinical baseline through the physical examination in, 76, 77
diet in, 75
drug, alcohol, and cigarette use in, 75
examination of male and female genitalia in, 79, 80
fundoscopic evaluation in, 77, 78
gastrointestinal assessment in, 79
general assessment in, 77
history of present illness in, 72, 73
history of sexually transmitted diseases in, 74, 75
initial laboratory profile in, 76
lymph node assessment in, 78
medication history in, 74
neurologic and musculoskeletal assessment in, 78, 79
oral cavity in, 77
past medical history in, 74
pet ownership and, 76
systems review in, 73, 74
travel history in, 75
nonnucleoside reverse transcriptase inhibitors in, 99, 100
nucleoside reverse transcriptase inhibitors in, 97–99
periodic clinical evaluation in, 80–86
degree of immune suppression and, 81
degree of viral activity and, 82, 83
immunologic and virologic baseline in, 80–83
laboratory tests in, 83–85
prevention of for nurses, 517, 518
primary care and case management of persons with, **71–94**
primary prevention of, absolutism in, 54–56
AIDS risk reduction model in, 63
behavior change theory of, 57, 61–64
components of effective programs of, 65
developing a structure for, 54–64
facilitating factors in, 65, 66
harm reduction in, 56, 57
health belief model in, 57
in the community, 65, 66
need for a theory base in, 54
needle and syringe exchange programs in, 56
realities of, **49–70**
sex education in, 56
social cognitive theory in, 57
theory of reasoned action in, 63
transtheoretical model of behavior change in, 63
prophylaxis for, antiretroviral, 107, 108
protease inhibitors in, 99, 101, 102
social contributions to, 50–54
stigma and marginalization in, heterosexism and, 51, 52
racism and, 53, 54
sexism and, 52, 53
syphilis testing in, 84
toxoplasmosis testing in, 85
tuberculin skin testing in, 86
vaccination against preventable illness and, 85
women with, supporting organizations for, 197–199
Hypodermis, 784
Hypoperfusion injury, as cause of skin disruption in infants, 912

Immigrant(s), Asian and Latino, acculturation and risk, relationship of, 363–365
as vulnerable populations, **359–380**
cancer in, 370, 371
diabetes in, 367–369
drug resistance among, 365
health of, 360–374
hepatitis B in, 370
human immunodeficiency virus disease in, 371, 372
knowledge and beliefs of, 366, 367
mental illness in, 372–374
morbidity and mortality of, 367–369
nursing care for, 374, 375
resources of, 361–363
risk factors of, 363–367
screening and health promotion for, 365, 366
tuberculosis and drug resistance in, 369
Indinavir, 101, 102
Infants, diaper dermatitis in, 916–918
pain assessment in, 852
pain management in, nonpharmacologic, 855–858
skin breakdown in, causes and prevention of, 909–914
prevention and management of, **907–920**
treatment of, 914–916
Infection(s), hospital-acquired, **443–461**
Infection control, **411–533**
in current health care marketplace, 419, 420
nurse's role in education and behavior change in, 420–424

Infection control (*continued*)
in home care settings, **463–482**
and medication storage during transport to the home, 469
and medication storage in the patient's home, 469
and parenteral medication preparation, 468
and storage of wound irrigating solution in, 470, 471
and surveillance of infections acquired during home care, 480
assessment of, 467
breathing circuits and, 473
cleaning and disinfection of patient care items and, 478, 479
developing a program for, 479–481
handwashing and, 465–467
home infusion therapy and, 467, 468
indwelling urinary catheter irrigation and meatal care and, 472
indwelling urinary catheter replacement and, 471
intermittent urethral catheterization and, 472
isolation precautions and, 474–477
occupational health policies and procedures and, 480, 481
prevention of catheter-related infections in, 468
quality improvement in, 481
respiratory therapy and, 473
respiratory tract suctioning and, 473, 474
tracheotomy care and, 474
urinary catheter maintenance and, 472
urinary tract care and, 471
wound care and, 469, 470
resources on, 523, 524
Infection control standards, **527–533**
Infectious disease, emerging, **427–442**
risk of occupational exposure to and infection with, **493–508**
airborne precautions and, 494, 495
contact precautions and, 495
droplet precautions and, 495
from bloodborne pathogens, 495–498
from cytomegalovirus, 498, 499
from head lice, 502
from hepatitis A, 499
from herpes simplex, 499, 500
from influenza, 500, 501
from meningitis, 501, 502
from mumps, 502
from pertussis, 503
from rubella, 503, 504
from rubeola, 504
from scabies, 504, 505
from tuberculosis, 505, 506
from varicella, 506, 507
standard precautions and, 494
transmission-based precautions and, 494, 495
Influenza, occupational exposure to, 500, 501
prevention of for nurses, 514, 515
Intravascular device(s), hospital-acquired infections related to, overview of, 446, 447
prevention of, 447–452
Ischemia-reperfusion injury, 792, 793
Itching, in human immunodeficiency virus infection, 141, 142

Joint Commission on Accreditation of Healthcare Organizations, 529, 531

Kuru, 428
Kyphosis, 560

Lamivudine, 97–99
Lamivudine/zidovudine (Combivir), 103
Latino immigrants, as vulnerable population, **359–380**
Lesbian women, access of to health care, 384, 385
as vulnerable population, **381–391**
cancer risk in, 386, 387
chemical dependency in, 388, 389
decreased societal and environmental resource availability to, 382, 383
depression in, 389
health problems of, **381–391**
case study of, 381, 382
human immunodeficiency virus disease in, 387, 388
quality of health care for, 384, 385
relative risk of, 385–389
risk of violence for, 385, 386
social connectedness of, 383, 384
Lice, occupational exposure to, 502
prevention of for nurses, 521
Lordosis, 560
Low birth weight, adolescent mothers and, 293
Lumbar puncture, in evaluation of central nervous system, 597, 598
Lyme disease, 435, 436

Malassezia pachydermatis, 436, 437
Managed care, glossary of terms used in, 233–235
  history of, 227–229
  human immunodeficiency virus infection and, **227–235**
  reform of, 232
Massage, in human immunodeficiency virus infection, 154–156
Measles, occupational exposure to, 503, 504
  prevention of for nurses, 509, 510
Medicaid, and the homeless, 269
Medicare, 336
Medicare + Choice, 336, 337
Meninges, 560
Meningitis, bacterial, prevention of for nurses, 516, 517
  occupational exposure to, 501, 502
  pathophysiology of, 763
  signs and symptoms of, 765
Mental illness, in Asian and Latino immigrants, 372–374
Methicillin-resistant *Staphylococcus aureus*, 437, 438
Motor function, assessment of, 582–585
Mourning process, 164, 165
  complicated, 165, 166
Mouth, dry, in human immunodeficiency virus infection, 140
Moyamoya disease, 703
Multiple sclerosis, 725–730
  bladder and bowel dysfunction in, 729
  classification of, 726, 727
  clinical presentation of, 728, 729
  cognitive impairment in, 729
  diagnosis of, 726, 727
  fatigue in, 729
  motor problems in, 728, 729
  pathophysiology of, 726
  patient and family resources for, 742
  sensory abnormalities in, 729
  treatment of, 730
  visual deficits in, 728
Mumps, occupational exposure to, 502
  prevention of for nurses, 509, 510
Myasthenia gravis, 731–734
  clinical presentation of, 731, 732
  diagnosis of, 732
  drug therapy for, 733
  management of, 732–734
  pathophysiology of, 731
  patient and family resources for, 742
  plasmapheresis for, 734
  surgery for, 734
Myelin sheath, 556
Myelography, in evaluation of central nervous system, 598, 599

National Institute for Occupational Safety and Health, 528
Nausea, in human immunodeficiency virus infection, 138, 139
Needle exchange programs, in prevention of human immunodeficiency virus infection, 56
Nelfinavir, 101, 102
Neonates, skin of, differences in, 908, 909
Nervous system, central, 555, 556
  peripheral, 555, 556
Neuroanatomy, basic components and cellular structures of, 555–558
  primer of, **555–572**
  supporting structures in, 559, 560
Neurodiagnostic studies, **593–605**
Neuroembryology, 558, 559
Neuroglial cells, 558
Neurologic assessment, documentation in, 589–591
Neurons, 556
Neurophysiology, primer of, **555–572**
Neuroscience health problems, 543, 544
Neuroscience nursing practice, acute and chronic illness continuum in, 544, 545
  changing health care delivery system and, 545, 546
  ethical perspectives in, **621–635**
  foundation of, 546–549
  future of, 552, 553
  in a new millennium, **541–554**
  models of, expansion and refinement of, 551, 552
  structure-process-outcomes model in, 549–551
Neuroscience patients, unique characteristics of, 542, 543
Neurosonology, 603
Neurotransmitters, 556
Nevirapine, 99, 100
Night sweats, in human immunodeficiency virus infection, 142
Nightingale, Florence, 148
Nosocomial infection(s), **443–461**
Nucleus pulposa, 560
Nurse as HIV/AIDS case manager, position statement on, 93, 94
Nutrition, in human immunodeficiency virus infection, 153, 154

Occupational Safety and Health Administration, 528, 529
Opportunistic infection(s), in human immunodeficiency virus infection, prophylaxis for, 109
Oral contraceptives, and stroke, 703

Organ donation, procurement, and transplantation, ethical issues in, 631
Oxygen, topical, in care of chronic wounds, 945

Pain, assessment tools for, 852
in human immunodeficiency virus infection, management of, 135–137
transmission of, physiology of, 848, 849
Pain management, drug therapy in, scientific basis of, 850
for persons with human immunodeficiency virus infection and acquired immunodeficiency syndrome, general principles of, 132, 133
in wound care, **847–860**
nonpharmacologic, 855–858
with medications, 852–855
fear of addiction in, 854, 855
Palliative care, for persons with human immunodeficiency virus infection and acquired immunodeficiency syndrome, **131–145**
scope of the problem of, 132
Parkinson's disease, 734–738
clinical presentation of, 735, 736
diagnosis of, 736
management of, 736–738
pathophysiology of, 735
patient and family resources for, 742
Parvovirus B19, and pregnant nurses, 523
Pathogen(s), emerging, **427–442**
Pediculosis, occupational exposure to, 502
Pertussis, occupational exposure to, 503
Pharyngitis, streptococcal, group A, prevention of for nurses, 520
Pia, 560
Pneumonia, hospital-acquired, overview of, 452, 453
prevention of, 453–456
Population(s), vulnerable. See *Vulnerable population(s).*
Positron emission tomography, in evaluation of central nervous system, 596, 597
Posterior cord syndrome, 668
Poverty, and human immunodeficiency virus infection epidemic, 50, 51
Pregnant nurse(s), infection control and, 522, 523
Pressure sore(s). See *Pressure ulcers.*
Pressure Sore Status Tool, 826
development and testing of, 839, 840
instructions for use of, 840–843
Pressure Sore Status Tool Rating Sheet, 843–845
Pressure Ulcer Scale for Healing Tool, 826
Pressure ulcers, 792, 793
as cause of skin disruption in infants, 912, 913
assessment of, tools for, 825–828
clinician education about, 868, 869
cycle of, interrupting, **861–871**
full thickness, with sepsis, clinical pathway for, 866, 867
improving outcomes of with risk assessment, 864–868
incidence of, 863, 864
measuring agency prevalence and incidence of, 863, 864
prevalence of, 863
prevention program for, unit-based quality improvement in, 869
Protease inhibitors, 99, 101, 102
pain medication and, in human immunodeficiency virus infection, 135, 136
Pruritus, in human immunodeficiency virus infection, 141, 142

Racism, and the stigma of human immunodeficiency virus infection, 53, 54
Rash(es), in human immunodeficiency virus infection, 141, 142
Rehabilitation and alternate levels of care, 613–615
Resistance, antiretroviral, 104–106
prevention of, 105, 106
Resource availability, in vulnerable populations model, 262–264, 348
Resuscitation, levels of, 629, 630
Ritonavir, 101, 102
pain medication and, in human immunodeficiency virus infection, 135, 136
Rubella, occupational exposure to, 503, 504
prevention of for nurses, 509, 510
Rubeola, occupational exposure to, 504

Saquinavir, 101, 102
Scabies, occupational exposure to, 504, 505
prevention of for nurses, 520, 521
Scoliosis, 560
Scrapie, 428
Seizures. See also *Epilepsy.*
acute, 745, 746
and epilepsy, **743–759**
assessment of, 746, 747
defining and classification of, 744, 745
precipitating factors in, 748
Sensory system function, assessment of, 585, 586
Service Employees International Union, 531
Sessing Scale, 825

Sex education, in prevention of human immunodeficiency virus infection, 56
Sexism, and the stigma of human immunodeficiency virus infection, 52, 53
Sexually transmitted diseases, history of, in primary care for persons with human immunodeficiency virus infection, 74, 75
in adolescent mothers, 293
Shingles, occupational exposure to, 506, 507
Skin, aging, 922, 923
anatomy, physiology, and pathophysiology of, **777–797**
anatomy of, 777–784, 907, 908
communicative function of, 787
immunologic function of, 787
metabolic and biochemical function of, 786
of neonates, differences in, 908, 909
pathophysiology of, 787–796
emerging concepts in, 792–796
key concepts in, 788–792
physiology of, 784–787, 907, 908
protective function of, 784, 785
sensory function of, 786
thermoregulatory function of, 785, 786
Skin breakdown, in infants, prevention and management of, **907–920**
Skin equivalents, 942–944
Skin grafts, 879
nursing care of, 880–882
procedures for, 880
Skin substitutes, 942–944
Skull, 559
Sleep disorders, in human immunodeficiency virus infection, 139, 140
Spaulding, Earle H., 484
Spaulding classification of disinfection of surgical instruments, 484, 485
Speech and language, assessment of, 576, 577
Spinal cord, 571
Spinal cord trauma, **661–687**
activity after, 683, 684
assessment of, 675
bladder function after, 682, 683
cardiovascular management after, 681, 682
complete, 668
continuum of care for, 673–675
acute, 674
at the accident scene, 673
diagnostics in, 674
emergency, 673, 674
gastrointestinal system after, 682
incomplete lesions in, 664, 665
mechanisms of, 668–673
motor testing after, 675–677
pain management in, 684
pathophysiology of, 662–664
psychological support following, 685
reflex testing after, 679
research on, 685, 686
respiratory care after, 680, 681
scope of, 661, 662
sensory testing after, 678
skin care management after, 683
spinal shock after, 679, 680
Spinal shock, 679, 680
bradycardia in, 680
hypotension in, 679
hypothermia in, 680
Spine, fractures of, 670
sacral, 671
thoracolumbar and thoracic, 671, 672
gunshot wounds to, 673
instability injuries of, 671
lower cervical, injury of, 670, 671
Staphylococcus aureus, multidrug-resistant, 437, 438
Status epilepticus, 759, 760
Stavudine, 97, 98
Sterilization, 483
versus disinfection, versus clean, **483–491**
Stratum basale, 781, 782
Stratum corneum, 778, 780
of premature infants, 908
Stratum granulosum, 780
Stratum lucidum, 780
Stratum spinosum, 780
Strep throat, prevention of for nurses, 520
Streptococcus pneumoniae, drug-resistant, 438, 439
Stroke, anticoagulant therapy for, 704
carotid artery syndromes in, 699, 700
classification of, 690, 691
clinical features and symptomatology of, 698–701
continuum of, **689–723**
cytoprotective strategies in, 705
diagnosis and management of, future trends in, 707
endovascular therapy for, 706
gene transfer therapy for, 706, 707
in young persons, 702, 703
investigation and diagnosis of, 701–703
history, examination, and laboratory tests in, 701, 702
laboratory investigations in, 714–717
neurologic and functional outcomes of, assessment of, 710–712
nursing management of, general guidelines for, 721–723
nursing practice guidelines for, 707–710
during the acute phase, 708
in patient, family, and caregiver education, 710
in rehabilitation phase, 708–710

Stroke (*continued*)
pathogenesis of, 695–698
prevention of, medical therapy for, 703, 704
surgical therapy for, 706
risk factors for, identification and modification of, 691–695
modifiable, 693, 694
nonmodifiable, 691–693
nursing role in modification of, 694, 695
scope of, 689
terminology and definition of, 689, 690
thrombolytic therapy for, 705
nursing guidelines for, 718–721
treatment of, 703–707
vertebrobasilar artery syndromes in, 700, 701
Suicide attempts, in adolescent mothers, 291, 292
Sulcus (sulci) of brain, 561, 562
Surgical site infections, hospital-acquired, overview of, 456, 457
prevention of, 457–459
Sussman Wound Healing Tool, 826
Synercid, 430
Syphilis, screening for, in persons with human immunodeficiency virus infection, 84

Takayasu disease, 703
Teenager(s), pregnant. See *Adolescent mothers.*
Thermal injury, as cause of skin disruption in infants, 910–912
Tissue transfers, in wound healing, 883–885
nursing care of, 889–892
procedures for, 885–888
Toxoplasmosis, screening for, in persons with human immunodeficiency virus infection, 85
Transcranial Doppler, 604
Trauma wounds. See also *Gunshot wounds.*
documentation of, 900–905
evidence in, 901, 903–905
management of, **895–906**
Triple drug therapy, for patients with AIDS, 107
Tuberculin skin testing, in persons with human immunodeficiency virus infection, 86
Tuberculosis, multidrug-resistant, 439, 440
in Asian and Latino immigrants, 369
occupational exposure to, 505, 506

Ulcer(s), decubitus. See *Pressure ulcers.*
pressure. See *Pressure ulcers.*
Ultrasound, therapeutic, in care of chronic wounds, 945
United States Department of Labor, 528
Urinary tract infection(s), hospital-acquired, overview of, 443, 444
prevention of, 444–446
signs and symptoms of, 444

Vaccination, against preventable illness, in persons with human immunodeficiency virus infection, 85
Vacuum-assisted closure, of chronic wounds, 945, 946
Vancomycin-resistant enterococci, 430, 431
Vancomycin-resistant *Staphylococcus aureus*, 437, 438
Varicella, occupational exposure to, 506, 507
prevention of for nurses, 515, 516
Vertebra(e), 559, 560
Vertebrobasilar artery syndromes, in stroke, 700, 701
Violence, and human immunodeficiency virus infection epidemic, 50, 51
Vital signs, in neurologic assessment, 586–589
Vitamin(s), and wound healing, 875, 876
Vitamin D, synthesis of, in skin, 786
Vitamin supplements, in human immunodeficiency virus infection, 149–152
Vomiting, in human immunodeficiency virus infection, 138, 139
Vulnerable population(s), adolescent mothers as, **289–299**
African Americans as, **345–357**
Asian and Latino immigrants as, **359–380**
battered women as, **301–312**
conceptual framework for studying, 346
depression in, youth and, **393–407**
gay and bisexual men as, **313–331**
homeless as, **261–274**
lesbian women as, **381–391**
model of, overview of, 302, 303
nursing care for, **261–407**
the elderly as, **333–343**
wives who care for husbands with dementia as, **275–287**

Warmth therapy, in care of chronic wounds, 946
Weakness, in human immunodeficiency virus infection, 134

Weight loss, involuntary, in human immunodeficiency virus infection, 137, 138
Welfare reform, and the homeless, 269
Whiplash, 669, 670
White matter, 561
Whooping cough, occupational exposure to, 503
Withholding and withdrawing therapies, 630
Women with acquired immunodeficiency syndrome, and their dependent children, 184, 185
  care of, **179–197**
  childbearing issues in, 182, 183
  coping strategies of, 187, 188
  cultural issues in, 183, 184
  depression in, 187
  Hispanic, 185
  interpersonal violence and, 185, 186
  major issues in, social, 183–186
  major issues of, 181–188
    clinical, 181–183
  nursing implications of, 190, 191
  psychologic issues in, 186–188
  socioeconomic factors in, 184
  special needs and considerations of, 189, 190
  supporting organizations for, 197–199
Work restrictions for health care personnel, 511–513
Wound(s), acute versus chronic, 788, 789
  chronic, adjunctive therapies for, 944–946
    biologic agents in care for, 942–944
    cleansing and irrigation of, 937–939
    debridement of, 937
    dressings in, 940, 941
    evaluating healability of, 935
    identifying goals and outcomes in management of, 936, 937
    in older adults, 923, 924
    nursing management of, **933–949**
    ongoing assessment of, 935, 936
    pain experience in, 850–852
    sterile versus nonsterile care for, 941, 942
    topical antibacterial therapy for, 939
    vacuum-assisted closure of, 945, 946
  cleansing and coverage of, 898
  closure of, 899
  depth and extent of, 789–791
  etiology of, 828–831
  from trauma. See *Trauma wounds.*
  in infants, treatment of, 914–916
  pathophysiology of, cytokines, growth factors, and other biomolecules in, 794, 795
    matrix synthesis and degradation in, 795, 796
  preoperative care for, 873–876
  primary closure of, 877, 878
    nursing care after, 879
    procedures for, 878, 879
  skin grafts for closure of, 879–882
  stages of, 814–819
  surgical alternatives for, **873–893**
Wound and Skin Intelligence System, 826
Wound assessment, chronic, **799–845**
  activity history in, 801, 802
  cardiovascular and respiratory systems in, 806, 807
  comprehensive assessment of total patient and, 799–811
  endocrine system in, 809, 810
  exudate type and amount in, 821–824
  focused patient history in, 800–804
  gastrointestinal and genitourinary systems in, 808, 809
  granulation tissue and epithelialization in, 824, 825
  infection and immunosuppression in, 805, 806
  location in, 812, 813
  medication history in, 801
  necrotic tissue type and amount in, 820, 821
  neurologic and musculoskeletal systems in, 809
  nutritional history in, 804
  pain assessment in, 810, 811
  peripheral vascular system in, 807, 808
  psychological history in, 803, 804
  sociologic history in, 802, 803
  surrounding tissue condition in, 824
  systems review and physical examination in, 805–810
  to evaluate therapeutic interventions, 832, 833
  wound characteristics in, 812–825
  wound edges in, 819
  wound size in, 813, 814
  wound stage in, 814–819
  wound undermining in, 819, 820
  tools for, 825–828
Wound care, evidence-based practice for, **955–963**
  for older adults, 928–930
  products for, categories of, 949–953
Wound healing, 896
  chronic, in older adults, **921–932**
  deterrents to, 897
  immunity and, 793, 794
  in older adults, factors affecting, 924–928

Wound healing (*continued*)
normal, 923
promotion of, 897
secondary, 876, 877
nursing care for, 877
stages of versus zones of activity in, 791, 792
tissues transfers for, 883–885
vitamins and, 875, 876
Wound Healing Scale, 825, 826

Zalcitabine, 97, 98
Zidovudine, 97, 98